BioSpace News Archive

TRxADE Telehealth Subsidiary Bonum Health to Provide Affordable Telemedicine Services to Patients at Leading Grocery Store Chain

Teknova , a leading manufacturer of cell culture media and supplements, protein purification buffers, and molecular biology reagents, announced today that Matt Lowell has joined the company as Chief Financial Officer (CFO). Lowell brings with him nearly 20 years of financial and strategic leadership experience

Polarisqb is proud to add Dr. Ian Reynolds, a world renowned expert in pharmacology, as an advisor to the company.

Indivumed GmbH announced a joint research collaboration to expand IndivuType by adding digital pathology images and data using cutting-edge technology from the Institute for Cancer Genetics and Informatics at Oslo University Hospital, a world leader in the application of Deep Learning and AI in oncology.

Leader in precision medicine recognized for bridging the gap between genetic science and clinical application to improve personalized medication safety

Following Multiple Years of Strong Growth, Financing Further Validates 503B Industry Value Proposition, Demonstrates Strength of QuVa Pharma and Attractiveness of Ongoing Business Growth Initiatives

Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today that its Founder and Chief Executive Officer, Brendan Frey, Ph.D., F.R.S.C., will participate in a panel discussion during the Citi PCA – Private Company Digital Health Conference *VIRTUAL* on May 20, 2021.

Worldwide Clinical Trials, Inc., the industry’s leading global, midsized, full-service contract research organization, announced that it was honored with five 2021 CRO Leadership Awards, presented by Clinical Leader and Life Science Leader.

Newly licensed technologies include use of Genprex’s TUSC2 gene therapy combined with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to TUSC2 therapy

Maxwell Biosciences , the biotechnology company behind the CLAROMER™ brand anti-infective drug platform, today announced Dr. John Lord has been appointed vice president, Research and Development. Dr. Lord will serve on Maxwell Bioscience’s Executive Committee, reporting to chief executive officer Joshua McClure.